Faridabad-
BRIC-Translational Health Science and Technology Institute (BRIC-THSTI), in collaboration with Miltenyi Biotec and the Biotechnology Industry Research Assistance Council (BIRAC), has announced India’s first hands-on training program on the Foundations of Cell and Gene Therapy (CGT) Manufacturing, with a special emphasis on CAR-T cell therapy.
The initiative aims to strengthen India’s translational research and clinical manufacturing capabilities by providing early-career scientists, clinicians and industry professionals with end-to-end exposure to the CGT development pipeline — spanning preclinical workflows, GMP-compliant manufacturing and clinical translation.
Titled “CAR-T Cell Therapy Manufacturing Hands-on Workshop and Symposia,” the three-day program will be held at THSTI, NCR Biotech Science Cluster, from 12–14 November 2025. Participants will first complete an online preparatory module through Miltenyi University, followed by immersive, practical sessions at THSTI’s cell and gene therapy facility.
The training integrates virtual coursework with facility-based learning to deliver comprehensive skill-building in CGT manufacturing. Key components include:
- Hands-on CAR-T cell manufacturing using Miltenyi’s CliniMACS Prodigy platform
- Cell analysis and quality-control workflows on the MACSQuant® Analyzer
- In-process and release testing aligned to CAR-T Express Mode protocols
- Continued access to Miltenyi University’s learning modules for post-workshop progression
“Cell and gene therapy can reach patients only when supported by strong infrastructure, skilled talent and robust manufacturing systems,” said Dr. Priya Kapoor G. Hingorani, Managing Director, Miltenyi Biotec India. “Through this partnership, we are helping build local, future-ready expertise to ensure that advanced therapies are translated sustainably in India.”
Prof. G. Karthikeyan, Executive Director, THSTI, added: “By combining academic rigor, industry experience and ecosystem enablement, this collaboration strengthens India’s position in the global CGT landscape.”
Dr. Jitendra Kumar, Managing Director, BIRAC, noted that BIRAC’s support reflects its commitment to enabling innovation-driven biomanufacturing: “Developing skilled human capital is central to expanding access to advanced therapies.”
Globally, cell and gene therapies are reshaping treatment for cancer, autoimmune disorders and rare diseases. India’s strategic investment in capacity-building and local manufacturing is expected to play a critical role in improving accessibility and affordability for patients.
